Omnicell, Inc. $OMCL Position Trimmed by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lowered its stake in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 7.4% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 592,144 shares of the company's stock after selling 47,397 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned approximately 1.26% of Omnicell worth $20,701,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Principal Financial Group Inc. raised its stake in Omnicell by 2.6% during the first quarter. Principal Financial Group Inc. now owns 244,644 shares of the company's stock valued at $8,553,000 after buying an additional 6,288 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Omnicell during the 1st quarter valued at approximately $2,073,000. Jane Street Group LLC lifted its stake in Omnicell by 7.4% during the fourth quarter. Jane Street Group LLC now owns 54,282 shares of the company's stock worth $2,417,000 after purchasing an additional 3,725 shares during the last quarter. GSA Capital Partners LLP acquired a new position in Omnicell in the first quarter worth $901,000. Finally, XTX Topco Ltd boosted its holdings in Omnicell by 316.1% in the first quarter. XTX Topco Ltd now owns 30,295 shares of the company's stock worth $1,059,000 after purchasing an additional 23,015 shares during the period. Institutional investors own 97.70% of the company's stock.

Wall Street Analyst Weigh In

OMCL has been the topic of a number of research reports. Bank of America increased their target price on shares of Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a report on Friday, May 23rd. Wall Street Zen lowered shares of Omnicell from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 9th. Wells Fargo & Company lifted their target price on Omnicell from $37.00 to $40.00 and gave the company an "overweight" rating in a research note on Monday, July 21st. Finally, Piper Sandler lowered their target price on Omnicell from $57.00 to $55.00 and set an "overweight" rating for the company in a report on Monday, August 11th. Four investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $46.71.

Omnicell Stock Performance

Omnicell stock traded down $0.91 during mid-day trading on Wednesday, hitting $31.86. 512,120 shares of the company's stock traded hands, compared to its average volume of 509,246. The company has a quick ratio of 1.24, a current ratio of 1.42 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a one year low of $22.66 and a one year high of $55.74. The firm has a 50 day moving average price of $30.59 and a 200 day moving average price of $31.21. The company has a market cap of $1.46 billion, a PE ratio of 63.72, a price-to-earnings-growth ratio of 7.16 and a beta of 0.82.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The company reported $0.45 EPS for the quarter, beating analysts' consensus estimates of $0.30 by $0.15. The company had revenue of $290.56 million for the quarter, compared to analyst estimates of $275.57 million. Omnicell had a return on equity of 4.27% and a net margin of 2.01%.The company's quarterly revenue was up 5.0% compared to the same quarter last year. During the same period last year, the company earned $0.51 earnings per share. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. On average, equities analysts forecast that Omnicell, Inc. will post 1.09 EPS for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.